Evidence map›Paper›PMID 41800118›Full record

ArticleBone reports2026

Uncoupled bone remodeling drives myeloma bone disease in Vk*MYC mouse model of multiple myeloma.

Clarissa Schmal, Marija K Simic, Ya Xiao, Alicia A Catala, Millie Jiang, Thomas Levin Andersen, Marta Diaz-delCastillo, Peter Croucher, Michelle McDonald, Abbas Jafari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Clarissa SchmalDepartment of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
Marija K SimicDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA.
Ya XiaoCancer Plasticity and Dormancy Program, Garvan Institute of Medical Research, Sydney, NSW, Australia.
Alicia A CatalaDepartment of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
Millie JiangSchool of Medical Science, Faculty of Medicine and Health, The University of Sydney.
Thomas Levin AndersenDepartment of Forensic Medicine, Aarhus University, Denmark.
Marta Diaz-delCastilloDepartment of Forensic Medicine, Aarhus University, Denmark.
Peter CroucherCancer Plasticity and Dormancy Program, Garvan Institute of Medical Research, Sydney, NSW, Australia.
Michelle McDonaldSchool of Medical Science, Faculty of Medicine and Health, The University of Sydney.
Abbas JafariDepartment of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM), the second-most frequent hematologic malignancy, is caused by the neoplastic expansion of clonal plasma cells. Up to 80% of MM patients develop myeloma bone disease (MMBD), a hallmark of which is the development of osteolytic lesions that can lead to skeletal related events such as fractures, spinal cord compression and bone pain. In the Vk*MYC mouse model of MM, MYC is expressed in germinal center B cells, facilitating the formation of malignant plasma cells and development of major characteristics of MM, including MMBD. However, the extent of skeletal changes and underlying cellular mechanisms in the Vk*MYC model has, to date, not been comprehensively described. Here, we provide such comprehensive characterization of MMBD and the associated structural and cellular changes in the femur of mice inoculated with the Vk*MYC cell line Vk14451. Vk*MYC mice developed significant osteolytic lesions in the femur. Serum analysis revealed a notable decrease in the bone formation marker amino terminal propeptide of type I procollagen (P1NP) (-33.3%,

Indexed as

Multiple myelomaMyeloma bone diseaseRemodelingVk*MYC

Identifiers

PMID41800118
PMCPMC12966676

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.